FIELD: medicine.
SUBSTANCE: blood is analysed for angiogenic factors: sFlt-1 - soluble fins-like tyrosine kinase and PIGF - placental growth factor. The coefficient K which is the sFlt-1 to PIGF relation is calculated. In this case, if K≥83, a management approach to pregnant women to be chosen shall use antihypertensive preparations and anticoagulants, and in case of K<83 pg/ml, the pregnant women are managed with no antihypertensive preparations used.
EFFECT: method enables clearly specifying the cases of required prescription of the antihypertensive preparations, as well as the cases when such prescription is not required, and moreover can have an unfavourable effect on foetus's health.
5 ex
| Title | Year | Author | Number |
|---|---|---|---|
| METHOD FOR PREDICTING EFFECTIVENESS OF TREATMENT OF MODERATE PREECLAMPSIA | 2020 |
|
RU2752715C1 |
| METHOD FOR CHOOSING MANAGEMENT APPROACH TO PREGNANT WOMEN WITH MODERATE PREECLAMPSIA | 2011 |
|
RU2477481C1 |
| METHOD FOR PREDICTING THE EFFECTIVENESS OF THE TREATMENT OF MODERATE PREECLAMPSIA | 2019 |
|
RU2705374C1 |
| METHOD FOR PREDICTION OF PREECLAMPSIA IN PREGNANT WOMEN SUFFERING FROM PLACENTAL INSUFFICIENCY | 2013 |
|
RU2545760C2 |
| METHOD FOR PREECLAMPSIA DIAGNOSTICS IN PREGNANT WOMEN WITH CHRONIC KIDNEY DISEASE | 2016 |
|
RU2623057C1 |
| METHOD FOR FORECASTING SEVERITY OF EARLY PREECLAMPSY | 2021 |
|
RU2753463C1 |
| METHOD FOR CHOOSING MANAGEMENT OF PREGNANT WOMEN WITH PLACENTAL INSUFFICIENCY AND FOETAL GROWTH INHIBITION SYNDROME | 2013 |
|
RU2517374C2 |
| METHOD FOR DIFFERENTIAL DIAGNOSIS OF ISOLATED PREECLAMPSIA AND PREECLAMPSIA, DEVELOPING ON THE BACKGROUND OF UNDIAGNOSED CHRONIC ARTERIAL HYPERTENSION | 2019 |
|
RU2713436C1 |
| METHOD OF PREDICTING THE RISK OF PRE-ECLAMPSIA IN PREGNANT WOMEN WITH TYPE 2 DIABETES MELLITUS | 2022 |
|
RU2800716C1 |
| METHOD OF PROLONGING PREGNANCY IN EARLY PRE-ECLAMPSIA | 2023 |
|
RU2803574C1 |
